BPTH (Bio-Path Holdings) EBITDA Margin %: 0.00% (As of Mar. 2026)


What is Bio-Path Holdings EBITDA Margin %?

Bio-Path Holdings BPTH +21.43% EBITDA Margin % is 0.00% as of Mar. 2026. The stock has 1 warning sign investors should review. Among 945 Biotechnology companies, Bio-Path Holdings ranks worse than 105820% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Bio-Path Holdings's EBITDA for the three months ended in Mar. 2026 was $-0.23 Mil. Bio-Path Holdings's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Bio-Path Holdings's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.

Bio-Path Holdings  (OTCPK:BPTH) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Bio-Path Holdings EBITDA Margin % Related Terms

Bio-Path Holdings EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Bio-Path Holdings's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bio-Path Holdings EBITDA Margin % Chart

Bio-Path Holdings Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Bio-Path Holdings Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Mar26
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

BPTH vs ADAPY, ZVSA, CLSDQ: EBITDA Margin % Comparison

For the Biotechnology subindustry, Bio-Path Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bio-Path Holdings EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bio-Path Holdings's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Bio-Path Holdings's EBITDA Margin % falls into.


Bio-Path Holdings EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Bio-Path Holdings's EBITDA Margin % for the fiscal year that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-11.833/0
= %

Bio-Path Holdings's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-0.234/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Bio-Path Holdings (BPTH) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Bio-Path Holdings and its competitors. According to the industry distribution chart, Bio-Path Holdings ranks #999999 out of 945 companies in the Biotechnology industry.
Is Bio-Path Holdings' EBITDA Margin % too high?
Bio-Path Holdings' current EBITDA Margin % is 0.00%. Based on the distribution chart, Bio-Path Holdings ranks #999999 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Bio-Path Holdings' EBITDA Margin % compare to ADAPY and ZVSA?
According to the Biotechnology industry distribution chart, Bio-Path Holdings ranks #999999 out of 945 companies for EBITDA Margin %. This places Bio-Path Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Bio-Path Holdings and its competitors. Bio-Path Holdings's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Path Holdings stock overvalued right now?
Bio-Path Holdings (BPTH) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Bio-Path Holdings (BPTH), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bio-Path Holdings Business Description

Address No. 2407, 625 Stanwix Street, Pittsburgh, PA, USA, 15222
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of a Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.